Trial ID or NCT#

NCT02683824

Status

not recruiting iconNOT RECRUITING

Purpose

This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and healthy volunteers. Integrins, such as integrin alpha-v-beta-6 (avb6), are a family of membrane receptors that are overexpressed on the cell surface of pancreatic cancers. [18F]-R01-MG-F2 targets avb6, which may improve early detection of and better stratify treatment options for patients with pancreatic cancer.

Official Title

Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes

Investigator(s)

Sanjiv Sam Gambhir, MD, PhD
Walter Park
Walter Park
Gastroenterologist, Pancreas specialist, Gastrointestinal specialist
Assistant Professor of Medicine (Gastroenterology and Hepatology) at the Stanford University Medical Center
Andrei Iagaru
Andrei Iagaru
Radiologist
Professor of Radiology (Nuclear Medicine) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Mahima Goel
(650) 723-0371